Cargando…

Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy

Background: There is no guideline recommendation for preventing hepatocellular carcinoma (HCC) recurrence after hepatic resection. Moreover, an unmet need exists on the effectiveness of sorafenib therapy in recurrent HCC. Purpose: We therefore assessed the efficacy and safety of sorafenib in Chinese...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Desheng, Jia, Weridong, Wang, Zhiming, Wen, Tianfu, Ding, Wei, Xia, Feng, Zhang, Ling, Wu, Feixiang, Peng, Tao, Liu, Bin, Zhou, Cuncai, Zheng, Qichang, Miao, Xiongying, Peng, Junping, Huang, Zhiyong, Dou, Kefeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6643495/ https://www.ncbi.nlm.nih.gov/pubmed/31410023 http://dx.doi.org/10.2147/OTT.S168447

Ejemplares similares

Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence
por: Lei, Jianyong, et al.
Publicado: (2016)

Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma
por: Wan, Xuying, et al.
Publicado: (2016)

Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib
por: Liu, Daizhong, et al.
Publicado: (2015)

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
por: Ye, Sheng-Long, et al.
Publicado: (2018)

Effectiveness of Sorafenib in Hepatic Hemangioma
por: Tiwari, Prateek, et al.
Publicado: (2017)

Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study
por: Ye, Sheng-Long, et al.
Publicado: (2015)

Efficacy of sorafenib adjuvant therapy in northwestern Chinese patients with non-metastatic renal-cell carcinoma after nephrectomy: A multicenter retrospective study
por: Wei, Di, et al.
Publicado: (2019)

The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
por: Wang, Li, et al.
Publicado: (2019)

Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
por: Zhuang, Lei, et al.
Publicado: (2017)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Sorafenib for Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Kim, Bo Hyun, et al.
Publicado: (2018)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

A Combination of Sorafenib, an Immune Checkpoint Inhibitor, TACE and Stereotactic Body Radiation Therapy versus Sorafenib and TACE in Advanced Hepatocellular Carcinoma Accompanied by Portal Vein Tumor Thrombus
por: Zhang, Zeyu, et al.
Publicado: (2022)

Giant cavernous hepatic hemangioma shrunk by use of sorafenib
por: Yamashita, Satoyoshi, et al.
Publicado: (2012)

Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy
por: Yao, Wang, et al.
Publicado: (2020)

NDRG2 Ameliorates Hepatic Fibrosis by Inhibiting the TGF-β1/Smad Pathway and Altering the MMP2/TIMP2 Ratio in Rats
por: Yang, Jiandong, et al.
Publicado: (2011)

Recurrent Hypoglycemia Triggered by Sorafenib Therapy in a Patient with Hemangiopericytoma
por: Lee, Si Won, et al.
Publicado: (2014)

Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018)

Complete Response to Sorafenib in Locally Recurrent Unresectable Aggressive Fibromatosis
por: Burney, Ikram A., et al.
Publicado: (2021)

Absence of antitumor effects of metformin in sorafenib-treated patients with hepatocellular carcinoma recurrence after hepatic resection and liver transplantation
por: Chung, Yong-Kyu, et al.
Publicado: (2018)

Sorafenib Plus Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
por: Peng, Peichun, et al.
Publicado: (2023)

Sorafenib Monotherapy in a Patient with Unresectable Hepatic Epithelioid Hemangioendothelioma
por: Kobayashi, Noritoshi, et al.
Publicado: (2016)

Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy
por: Wei, Meng-Chao, et al.
Publicado: (2022)

Layered Double Hydroxides-Loaded Sorafenib Inhibit Hepatic Stellate Cells Proliferation and Activation In Vitro and Reduce Fibrosis In Vivo
por: Peng, Wei, et al.
Publicado: (2022)

Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation
por: Zhang, Xia, et al.
Publicado: (2023)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma
por: Zhang, Yingqiang, et al.
Publicado: (2020)

Specific adverse events predict survival rates in a Chinese population diagnosed with hepatocellular carcinoma and treated with sorafenib
por: Lee, Shou‐Wu, et al.
Publicado: (2018)

Sorafenib treatment on Chinese patients with advanced hepatocellular carcinoma: A study on prognostic factors of the viral and tumor status
por: Lee, Shou-Wu, et al.
Publicado: (2019)

Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma
por: Ye, Ding-Wei, et al.
Publicado: (2014)

Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?
por: Huang, Yun, et al.
Publicado: (2019)

Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor
por: Musso, Orlando, et al.
Publicado: (2019)

Sorafenib Attenuates Fibrotic Hepatic Injury Through Mediating Lysine Crotonylation
por: Chen, Xiao-Feng, et al.
Publicado: (2022)

Polymeric nanomedicines for the treatment of hepatic diseases
por: Luo, Feixiang, et al.
Publicado: (2022)

Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection
por: Zheng, Liming, et al.
Publicado: (2021)

Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
por: Liu, Bao-Jiang, et al.
Publicado: (2020)

Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus
por: Zhang, Yong-Fa, et al.
Publicado: (2016)

Downregulation of miR-200a Induces EMT Phenotypes and CSC-like Signatures through Targeting the β-catenin Pathway in Hepatic Oval Cells
por: Liu, Jie, et al.
Publicado: (2013)

High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
por: Xu, Jianjun, et al.
Publicado: (2022)

Efficacy of TACE+Radiofrequency Ablation+Sorafenib in the Treatment of Patients with Recurrent Liver Cancer and Construction of Prediction Model
por: Sun, Aimin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v7dh7lo0p7qpnv69q8gabmdu23